Study and Reporting of Adverse Drug Reaction Patterns Among Organ Transplant Patients Receiving Tacrolimus Therapy in a Real World Post-Marketing Experience
Shobharam Sahu*1, Poonam Rishishwar1, Chhaya Rathod2
1Faculty of Pharmaceutical science,Sri Venkateshwara University, Gajraula, UP, India
2Rajiv Gandhi college of Pharmacy, Nautanwa-Maharajganj, UP, India
Received: 01-Oct-2017 , Accepted: 05-Feb-2018
Keywords: Tacrolimus, Immunosuppressant, Solid organ transplant, Grafts rejection, Adverse drug reaction reporting, Adverse events
Full Text HTML
How to Cite this Article
Sahu S, Rishishwar P, Rathod C. Study and Reporting of Adverse Drug Reaction Patterns Among Organ Transplant Patients Receiving Tacrolimus Therapy in a Real World Post-Marketing Experience. UKJPB. 2018;6(1): 33-38.
With the availability of many immunosuppressive drugs for treatment of solid organ transplantation increase to a life span of patients who is receiving tacrolimus separately for End Stage of liver, heart and lung, kidney. But after all success of solid organ transplantation is purely dependent on proper course of immunosuppressive therapy. Tacrolimus is lactones antibiotic isolated from the fermentation of streptomyces tstkubaeis. This calcineurin inhibitor widely used for its immunosuppressive properties to increase patient survival and prevent graft function, organ rejection in solid organ transplant and graft-versus-host disease in transplant patients suppresses to enzyme for the growth of B cells and T cells. It was first approved for use to prevent graft rejection in 1994 for liver transplantation and in 1997 for kidney transplantation. The outcomes of this drug have varied due to differences in induction and maintenance therapy, drug dosing and monitoring. The aim of this study of an assessment and reporting of adverse drug reaction was to analyze the case reports of literature critically, conducted to monitor and evaluated the adverse events (AEs) and adverse drug reactions (ADRs) of immunosuppressive drug regimens, its causality, severity in therapy which is used various organ transplant patients and to document the pharmacotherapeutic actions taken for its management.